Cargando…

Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer

BACKGROUND: Mps one binder kinase activator 1 (MOB1) is a core component of the Hippo signaling pathway and has been implicated as a tumor suppressor. Here, we evaluated the possible relationship of MOB1 expression in non‐small cell lung cancer (NSCLC) to prognosis. METHODS: We retrospectively analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Nobuhisa, Tanaka, Kentaro, Otsubo, Kohei, Toyokawa, Gouji, Ikematsu, Yuki, Ide, Maako, Yoneshima, Yasuto, Iwama, Eiji, Inoue, Hiroyuki, Ijichi, Kayo, Tagawa, Tetsuzo, Nakanishi, Yoichi, Okamoto, Isamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529568/
https://www.ncbi.nlm.nih.gov/pubmed/32841529
http://dx.doi.org/10.1111/1759-7714.13608
_version_ 1783589461392621568
author Ando, Nobuhisa
Tanaka, Kentaro
Otsubo, Kohei
Toyokawa, Gouji
Ikematsu, Yuki
Ide, Maako
Yoneshima, Yasuto
Iwama, Eiji
Inoue, Hiroyuki
Ijichi, Kayo
Tagawa, Tetsuzo
Nakanishi, Yoichi
Okamoto, Isamu
author_facet Ando, Nobuhisa
Tanaka, Kentaro
Otsubo, Kohei
Toyokawa, Gouji
Ikematsu, Yuki
Ide, Maako
Yoneshima, Yasuto
Iwama, Eiji
Inoue, Hiroyuki
Ijichi, Kayo
Tagawa, Tetsuzo
Nakanishi, Yoichi
Okamoto, Isamu
author_sort Ando, Nobuhisa
collection PubMed
description BACKGROUND: Mps one binder kinase activator 1 (MOB1) is a core component of the Hippo signaling pathway and has been implicated as a tumor suppressor. Here, we evaluated the possible relationship of MOB1 expression in non‐small cell lung cancer (NSCLC) to prognosis. METHODS: We retrospectively analyzed 205 lung adenocarcinoma patients treated at Kyushu University Hospital between November 2007 and October 2012. MOB1 expression in tumor cells of surgical specimens was evaluated by immunohistochemistry. Invasive activity of NSCLC cell lines in vitro was measured with a transwell assay. RESULTS: Expression of MOB1 was classified as high in 105 of the 205 (51.2%) tumor specimens, and such high expression was significantly associated with poor disease‐free survival (P = 0.0161). Among the various clinicopathologic parameters examined, high MOB1 expression was significantly associated only with intratumoral vascular invasion (P = 0.0005). Multivariate analysis also identified high MOB1 expression as a significant independent risk factor for disease‐free survival (P = 0.0319). The invasiveness of H1299 cells in vitro was increased or attenuated by overexpression or knockdown of MOB1, respectively. CONCLUSIONS: Our results suggest that MOB1 might promote early recurrence of NSCLC by increasing vascular invasion by tumor cells. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: We found that high MOB1 expression in surgical specimens of lung adenocarcinoma was associated with poor disease‐free survival and with intratumoral vascular invasion. MOB1 expression also promoted the invasiveness of NSCLC cells in vitro. WHAT THIS STUDY ADDS: Our results thus suggest that high MOB1 expression is a risk factor for early postoperative recurrence in lung adenocarcinoma.
format Online
Article
Text
id pubmed-7529568
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-75295682020-10-05 Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer Ando, Nobuhisa Tanaka, Kentaro Otsubo, Kohei Toyokawa, Gouji Ikematsu, Yuki Ide, Maako Yoneshima, Yasuto Iwama, Eiji Inoue, Hiroyuki Ijichi, Kayo Tagawa, Tetsuzo Nakanishi, Yoichi Okamoto, Isamu Thorac Cancer Original Articles BACKGROUND: Mps one binder kinase activator 1 (MOB1) is a core component of the Hippo signaling pathway and has been implicated as a tumor suppressor. Here, we evaluated the possible relationship of MOB1 expression in non‐small cell lung cancer (NSCLC) to prognosis. METHODS: We retrospectively analyzed 205 lung adenocarcinoma patients treated at Kyushu University Hospital between November 2007 and October 2012. MOB1 expression in tumor cells of surgical specimens was evaluated by immunohistochemistry. Invasive activity of NSCLC cell lines in vitro was measured with a transwell assay. RESULTS: Expression of MOB1 was classified as high in 105 of the 205 (51.2%) tumor specimens, and such high expression was significantly associated with poor disease‐free survival (P = 0.0161). Among the various clinicopathologic parameters examined, high MOB1 expression was significantly associated only with intratumoral vascular invasion (P = 0.0005). Multivariate analysis also identified high MOB1 expression as a significant independent risk factor for disease‐free survival (P = 0.0319). The invasiveness of H1299 cells in vitro was increased or attenuated by overexpression or knockdown of MOB1, respectively. CONCLUSIONS: Our results suggest that MOB1 might promote early recurrence of NSCLC by increasing vascular invasion by tumor cells. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: We found that high MOB1 expression in surgical specimens of lung adenocarcinoma was associated with poor disease‐free survival and with intratumoral vascular invasion. MOB1 expression also promoted the invasiveness of NSCLC cells in vitro. WHAT THIS STUDY ADDS: Our results thus suggest that high MOB1 expression is a risk factor for early postoperative recurrence in lung adenocarcinoma. John Wiley & Sons Australia, Ltd 2020-08-25 2020-10 /pmc/articles/PMC7529568/ /pubmed/32841529 http://dx.doi.org/10.1111/1759-7714.13608 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Ando, Nobuhisa
Tanaka, Kentaro
Otsubo, Kohei
Toyokawa, Gouji
Ikematsu, Yuki
Ide, Maako
Yoneshima, Yasuto
Iwama, Eiji
Inoue, Hiroyuki
Ijichi, Kayo
Tagawa, Tetsuzo
Nakanishi, Yoichi
Okamoto, Isamu
Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
title Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
title_full Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
title_fullStr Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
title_full_unstemmed Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
title_short Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
title_sort association of mps one binder kinase activator 1 (mob1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529568/
https://www.ncbi.nlm.nih.gov/pubmed/32841529
http://dx.doi.org/10.1111/1759-7714.13608
work_keys_str_mv AT andonobuhisa associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT tanakakentaro associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT otsubokohei associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT toyokawagouji associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT ikematsuyuki associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT idemaako associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT yoneshimayasuto associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT iwamaeiji associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT inouehiroyuki associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT ijichikayo associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT tagawatetsuzo associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT nakanishiyoichi associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer
AT okamotoisamu associationofmpsonebinderkinaseactivator1mob1expressionwithpoordiseasefreesurvivalinindividualswithnonsmallcelllungcancer